Canceropôle Île-de-France and the PSCC are joining forces to accelerate innovation in oncology in the Île-de-France region
- Jun 12
- 1 min read
The Paris-Saclay Cancer Cluster (PSCC) and Cancéropôle Île-de-France have formalised their partnership with a shared objective: to strengthen coordination within the Île-de-France cancer research ecosystem by establishing a more coherent link between academic research, scientific coordination and innovation..
Driven by a shared vision of the research–innovation continuum, the two organisations have identified synergies: Cancéropôle Île-de-France focuses primarily on supporting early-stage projects and fostering the regional scientific community, whilst the PSCC specialises in supporting innovative projects with high potential.
Four areas of operational collaboration
The partnership is structured around four specific areas, defined jointly.
Area 1
Joint scientific coordination and collaboration
Organisation of joint sessions dedicated to translational innovation — AI, data, biomarkers, early-stage trials — and cross-participation in the flagship events of both organisations, including the PSCC Innovation Forum.
Area 2
Mapping and interconnection of platforms
Development of a joint map of regional platforms (imaging, genomics, bioinformatics, AI, etc.) and linking of PSCC platform managers with Cancéropôle working groups.
Area 3
Support for the emergence and transfer of projects
Interconnection of support mechanisms and bilateral project guidance: early-stage projects directed towards Cancéropôle, projects with commercialisation potential directed towards the PSCC.
Area 4
Communication and strategic coordination
Establishment of a quarterly liaison group and cross-sharing of news: calls for projects, Cancéropôle and PSCC events, and preparation of joint communications.
A collaborative approach for the benefit of patients
This partnership is part of a shared ambition: to ultimately improve the care of cancer patients in the Île-de-France region. By strengthening synergies between academic, clinical and industrial stakeholders, the two organisations aim to help bring new therapies and innovative diagnostic tools to market more quickly.
